Bruker today announced that it has acquired PMOD Technologies LLC, a highly respected provider of research-use-only software for preclinical and molecular imaging, with a focus on molecular quantification and pharmacokinetic modeling. The PMOD software is widely used for the analysis of positron emission tomography (PET) studies in neurology, cardiology and oncology, both for preclinical and human molecular imaging research. Founded in 2003 as a University Hospital Zuerich spin-off, PMOD Technologies is based in Zuerich and has an innovative development team in Warsaw, Poland. The acquisition confirms Bruker's commitment to provide intuitive end-to-end solutions that make image analysis and quantitative knowledge extraction in nuclear molecular imaging research more productive and precise.
Do you want to learn more? Read the whole article, or jus ask us!